Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

21.22
-1.1600-5.18%
Post-market: 21.220.00000.00%19:14 EDT
Volume:1.36M
Turnover:29.21M
Market Cap:2.63B
PE:-167.27
High:22.53
Open:22.23
Low:21.13
Close:22.38
52wk High:31.77
52wk Low:11.86
Shares:124.03M
Float Shares:88.24M
Volume Ratio:0.87
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1269
EPS(LYR):-0.1269
ROE:-9.30%
ROA:-1.95%
PB:13.89
PE(LYR):-167.27

Loading ...

Crude Oil Falls Over 2%; PayPal Shares Spike Higher

Benzinga
·
Oct 29, 2025

Arcutis Biotherapeutics rises 26.5%

TIPRANKS
·
Oct 29, 2025

Arcutis Biotherapeutics Up Over 27%, on Pace for Largest Percent Increase Since February 2021 -- Data Talk

Dow Jones
·
Oct 28, 2025

Stock Track | Arcutis Biotherapeutics Soars Nearly 20% Pre-Market on Strong Q3 Results and Positive 2026 Outlook

Stock Track
·
Oct 28, 2025

Arcutis Biotherapeutics' Q3 revenue jumps to $99.2 mln

Reuters
·
Oct 28, 2025

Earnings Flash (ARQT) Arcutis Biotherapeutics Posts Q3 EPS $0.06, vs. FactSet Est of $0.10 Loss

MT Newswires Live
·
Oct 28, 2025

Stock Track | Arcutis Biotherapeutics Soars 8.45% Pre-Market on Strong Q3 Results and Positive 2026 Outlook

Stock Track
·
Oct 28, 2025

Stock Track | Arcutis Biotherapeutics Soars 8.45% Pre-Market on Strong Q3 Results and Positive 2026 Outlook

Stock Track
·
Oct 28, 2025

Arcutis Biotherapeutics Q3 EPS $0.06 Beats $(0.10) Estimate, Sales $99.219M Beat $86.978M Estimate

Benzinga
·
Oct 28, 2025

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

THOMSON REUTERS
·
Oct 28, 2025

Arcutis Biotherapeutics - Provides Initial 2026 Full Year Net Product Sales Guidance of $455–$470 Million

THOMSON REUTERS
·
Oct 28, 2025

Arcutis Biotherapeutics Q3 Operating Expenses USD 90.693 Million

THOMSON REUTERS
·
Oct 28, 2025

Arcutis Biotherapeutics Q3 Operating Income USD 8.526 Million

THOMSON REUTERS
·
Oct 28, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 27, 2025

Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
Oct 25, 2025

Arcutis Biotherapeutics presents quality of life, long-term data on ZORYVE

TIPRANKS
·
Oct 24, 2025

Arcutis Reports ZORYVE Cream Improves Sleep and Long-Term Disease Control in Atopic Dermatitis Patients

Reuters
·
Oct 24, 2025

Arcutis Biotherapeutics (ARQT): Examining Valuation After FDA Expansion of ZORYVE to Young Children

Simply Wall St.
·
Oct 20, 2025

Morgan Stanley Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
Oct 17, 2025

Top Executive Sells Thousands of Arcutis Biotherapeutics Shares!

TIPRANKS
·
Oct 07, 2025